secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095408
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q2 net loss $63.2M; cash $460M; in-licenses RAS drugs, begins Phase 3
----------------------------------------------------------------------------

- Net loss $63.2M ($0.29/share) vs $31.8M ($0.21/share) YOY; R&D $33M including $22.5M in-license payments.
- Cash, equivalents & securities $460.2M (up from $322M Dec 2023); runway into H1 2027.
- In-licensed pan-RAS glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001; IND filings H1 2025 and Q1 2025.
- Initiated SEACRAFT-2 Phase 3 trial for naporafenib + trametinib in NRASm melanoma; randomized data 2025.
- Phase 1b combo data in RAS Q61X tumors expected Q4 2024; initial monotherapy data for ERAS-0015/4001 in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/0000950170-24-095408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/eras-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer